| First Author | Sclip A | Year | 2011 |
| Journal | J Biol Chem | Volume | 286 |
| Issue | 51 | Pages | 43871-80 |
| PubMed ID | 22033930 | Mgi Jnum | J:178748 |
| Mgi Id | MGI:5300090 | Doi | 10.1074/jbc.M111.297515 |
| Citation | Sclip A, et al. (2011) c-Jun N-terminal Kinase Regulates Soluble Abeta Oligomers and Cognitive Impairment in AD Mouse Model. J Biol Chem 286(51):43871-80 |
| abstractText | Alzheimer disease (AD) is characterized by cognitive impairment that starts with memory loss to end in dementia. Loss of synapses and synaptic dysfunction are closely associated with cognitive impairment in AD patients. Biochemical and pathological evidence suggests that soluble Abeta oligomers correlate with cognitive impairment. Here, we used the TgCRND8 AD mouse model to investigate the role of JNK in long term memory deficits. TgCRND8 mice were chronically treated with the cell-penetrating c-Jun N-terminal kinase inhibitor peptide (D-JNKI1). D-JNKI1, preventing JNK action, completely rescued memory impairments (behavioral studies) as well as the long term potentiation deficits of TgCRND8 mice. Moreover, D-JNKI1 inhibited APP phosphorylation in Thr-668 and reduced the amyloidogenic cleavage of APP and Abeta oligomers in brain parenchyma of treated mice. In conclusion, by regulating key pathogenic mechanisms of AD, JNK might hold promise as innovative therapeutic target. |
